Ceftaroline Fosamil: A Brief Clinical Review

被引：29
作者：
Shirley D.-A.T. [1 ]
Heil E.L. [2 ]
Johnson J.K. [3 ,4 ]
机构：
[1] Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore
[2] Department of Pharmacy, University of Maryland Medical Center, Baltimore
[3] Departments of Pathology and Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, 21201
[4] Microbiology and Virology Laboratories, University of Maryland Medical Center, Baltimore, MD, 21201
来源：
Infectious Diseases and Therapy | 2013年 / 2卷 / 2期
关键词：
Avibactam; Bacterial infection; Ceftaroline; Cephalosporin; Community-acquired infection; Methicillin-resistant S. aureus; Pneumonia; S; aureus; pneumoniae; Skin infection;
D O I：
10.1007/s40121-013-0010-x
中图分类号：
学科分类号：
摘要：
Ceftaroline is a novel cephalosporin with a favorable tolerability profile and broad in vitro activity against many resistant Gram-positive and common Gram-negative organisms. Ceftaroline fosamil is the first cephalosporin to be approved by the United States Food and Drug Administration (FDA) for the treatment of adults with acute bacterial skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is also approved by the FDA for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae (with or without concurrent bacteremia), although there are no data at this time to support the use of ceftaroline fosamil for the treatment of pneumonia caused by MRSA. Ceftaroline fosamil is likewise approved by the European Commission for the treatment of adults with complicated skin and soft tissue infections or community-acquired pneumonia. This review summarizes the pharmacokinetic and microbiologic properties of ceftaroline, as well as the safety and efficacy data that led to its approval by the FDA in 2010 and the European Commission in 2012. Future directions to be addressed are also highlighted. © 2013 The Author(s).
引用
收藏
页码：95 / 110
页数：15
相关论文
共 92 条
[61]  
Malincarne L., Francisci D., Martinelli L., Masini G., Baldelli F., A case of severe cefepime-related neutropenia in a 15-year-old patient, Scand J Infect Dis, 42, pp. 156-157, (2010)
[62]  
Hersh A.L., Chambers H.F., Maselli J.H., Gonzales R., National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections, Arch Intern Med, 168, pp. 1585-1591, (2008)
[63]  
Edelsberg J., Taneja C., Zervos M., Et al., Trends in US hospital admissions for skin and soft tissue infections, Emerg Infect Dis, 15, pp. 1516-1518, (2009)
[64]  
(2007)
[65]  
HCUP facts and figures: Statistics on hospital-based care in the United States Rockville, (2009)
[66]  
Dukic V.M., Lauderdale D.S., Wilder J., Daum R.S., David M.Z., Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis, PLoS ONE, 8, (2013)
[67]  
Sakoulas G., Moellering Jr. R.C., Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains, Clin Infect Dis, 46, (2008)
[68]  
Lodise T.P., Graves J., Evans A., Et al., Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin, Antimicrob Agents Chemother, 52, pp. 3315-3320, (2008)
[69]  
Kim S.H., Kim K.H., Kim H.B., Et al., Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia, Antimicrob Agents Chemother, 52, pp. 192-197, (2008)
[70]  
Gerson S.L., Kaplan S.L., Bruss J.B., Et al., Hematologic effects of linezolid: summary of clinical experience, Antimicrob Agents Chemother, 46, pp. 2723-2726, (2002)
12345678910